Literature DB >> 24547956

Stellate ganglion block promotes recovery of Bell's palsy in patients with diabetes mellitus.

Guo-Dong Liu1, Chun-Jing He.   

Abstract

CONCLUSION: Stellate ganglion block (SGB) is effective for treatment of Bell's palsy in patients with diabetes mellitus.
BACKGROUND: Corticosteroids are widely used for treatment of Bell's palsy in patients with diabetes mellitus but may induce complications like hyperglycemia, which calls for an alternative therapy. This study aimed to ascertain the effect of SGB on Bell's palsy in patients with diabetes mellitus.
METHODS: This randomized and single-blinded clinical trial involved 96 diabetic patients with Bell's palsy that were randomly divided into a control group (n = 48) and a treatment group (SGB group, n = 48). The House-Brackmann scale and facial disability index (FDI, including FDIP and FDIS) were observed before treatment and at 1 and 3 months after treatment for assessment of the outcome.
RESULTS: No statistically significant difference was found between the two groups before treatment as regards the House-Brackmann scale and FDI. There was a statistically significant difference in FDIP score in the two groups after treatment in comparison with before treatment. The FDIS score showed a statistical difference between the two groups after treatment.

Entities:  

Keywords:  FDI; House-Brackmann scale; facial disability index

Mesh:

Year:  2014        PMID: 24547956     DOI: 10.3109/00016489.2014.880794

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  2 in total

1.  Effect of a Stellate Ganglion Block on Acute Lung Injury in Septic Rats.

Authors:  Yong Chen; Lian Guo; Haili Lang; Xiaolan Hu; Sun Jing; Mengsi Luo; Guohai Xu; Zhidong Zhou
Journal:  Inflammation       Date:  2018-10       Impact factor: 4.092

2.  Intratympanic Steroid Treatment of Bell's Palsy in Patients with Comorbid Disease: A Preliminary Report.

Authors:  Deniz Demir; Sena Genç; Mehmet Güven; Mahmut Sinan Yılmaz; Ahmet Kara; Ünal Erkorkmaz
Journal:  J Int Adv Otol       Date:  2020-04       Impact factor: 1.017

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.